Novartis | Novartis | wage and hour violation | 2012 | private lawsuit-federal | $99,000,000 |
Janssen Pharmaceuticals | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Mylan Laboratories, Inc. | Viatris | consumer protection violation | 2000 | FTC | $100,000,000 |
Mallinckrodt ARD Inc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | FTC | $100,000,000 |
Astellas Pharma US Inc. | Astellas Pharma | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $100,000,000 |
Mallinckrodt plc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $100,000,000 |
Organon USA Inc. | Organon & Co. | drug or medical equipment safety violation | 2018 | private lawsuit-federal | $100,000,000 |
GlaxoSmithKline PLC | GlaxoSmithKline | price-fixing or anti-competitive practices | 2005 | private lawsuit-federal | $100,000,000 |
Indivior Inc. | Indivior PLC | price-fixing or anti-competitive practices | 2023 | MULTI-AG | $102,500,000 |
Novartis Pharmaceuticals Corp. | Novartis | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
GlaxoSmithKline, LLC | GlaxoSmithKline | kickbacks and bribery | 2014 | MULTI-AG | $105,000,000 |
Mylan Laboratories et al. | Viatris | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $108,000,000 |
Sanofi-Aventis U.S. Inc. | Sanofi | False Claims Act and related | 2012 | DOJ_CIVIL | $109,000,000 |
AstraZeneca | AstraZeneca | False Claims Act and related | 2018 | TX-AG | $110,000,000 |
Novartis AG | Novartis | Foreign Corrupt Practices Act | 2020 | SEC | $112,800,000 |
Avanir Pharmaceuticals | Otsuka Pharmaceutical | False Claims Act and related | 2019 | DOJ_CIVIL | $115,874,895 |
Cephalon Inc. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $116,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $116,860,000 |
Mylan Pharmaceuticals and UDL Laboratories | Viatris | False Claims Act and related | 2009 | DOJ_CIVIL | $118,000,000 |
Mylan Pharmaceuticals, Inc. | Viatris | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $118,000,000 |
Actavis Mid-Atlantic LLC | Teva Pharmaceutical Industries | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $118,614,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
Allergan PLC | AbbVie | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $120,000,000 |
King Pharmaceuticals | Pfizer | False Claims Act and related | 2005 | DOJ_CIVIL | $124,000,000 |
King Pharmaceuticals | Pfizer | False Claims Act and related | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $124,000,000 |
Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Cephalon | Teva Pharmaceutical Industries | consumer protection violation | 2016 | MULTI-AG | $125,000,000 |
Abbott Laboratories Inc. | AbbVie | False Claims Act and related | 2010 | DOJ_CIVIL | $126,500,000 |
Novartis AG | Novartis | price-fixing or anti-competitive practices | 2023 | private lawsuit-federal | $126,850,000 |
Hoffmann-La Roche | Roche | price-fixing or anti-competitive practices | 2000 | private lawsuit-federal | $130,000,000 |
Allergan Ltd. et al. | AbbVie | off-label or unapproved promotion of medical products | 2022 | FL-AG | $134,200,000 |
Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
Valeant Pharmaceuticals International, Inc. | Bausch Health | investor protection violation | 2017 | MULTI-AG | $145,000,000 |
Impax Laboratories, Inc. | Amneal Pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $145,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | False Claims Act and related | 2010 | USAO | $149,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
GlaxoSmithKline | GlaxoSmithKline | False Claims Act and related | 2005 | DOJ_CIVIL | $150,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | product safety violation | 2022 | private lawsuit-federal | $150,000,000 |
GlaxoSmithKline PLC | GlaxoSmithKline | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $150,000,000 |
Lupin Pharmaceuticals Inc. | Lupin Limited | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $150,000,000 |
Sandoz Inc. | Sandoz Group | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $150,000,000 |
TAP Pharmaceutical Products | Takeda Pharmaceutical | price-fixing or anti-competitive practices | 2005 | private lawsuit-federal | $150,000,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Par Pharmaceuticals, Inc. | Endo International | False Claims Act and related | 2011 | MULTI-AG | $154,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act and related | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $160,000,000 |
SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $163,560,000 |
Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | False Claims Act and related | 2010 | MULTI-AG | $169,000,000 |
Endo Health Solution | Endo International | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
Novartis Corporation | Novartis | employment discrimination | 2010 | private lawsuit-federal | $175,000,000 |
GlaxoSmithKline | GlaxoSmithKline | price-fixing or anti-competitive practices | 2004 | private lawsuit-federal | $175,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Sandoz Inc. | Sandoz Group | False Claims Act and related | 2021 | DOJ_CIVIL | $185,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | False Claims Act and related | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $187,000,000 |
Aventis Pharmaceuticals Inc. | Sanofi | False Claims Act and related | 2007 | DOJ_CIVIL | $190,000,000 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Pfizer Inc. | Pfizer | price-fixing or anti-competitive practices | 2014 | private lawsuit-federal | $190,000,000 |
Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Sandoz Inc. | Sandoz Group | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $195,000,000 |
AstraZeneca | AstraZeneca | drug or medical equipment safety violation | 2010 | private lawsuit-federal | $198,000,000 |
Allergan Finance LLC | AbbVie | off-label or unapproved promotion of medical products | 2021 | NY-AG | $200,000,000 |
Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Elan Corporation PLC | Perrigo | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
United Therapeutics Corporation | United Therapeutics | False Claims Act and related | 2017 | DOJ_CIVIL | $210,000,000 |
Taro Pharmaceuticals USA, Inc. | Sun Pharmaceuticals | False Claims Act and related | 2021 | DOJ_CIVIL | $213,200,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $220,000,000 |
Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | TX-AG | $225,000,000 |
Barr Laboratories Inc. | Teva Pharmaceutical Industries | price-fixing or anti-competitive practices | 2017 | private lawsuit-state | $225,000,000 |
Novartis Hellas S.A.C.I. et al. | Novartis | Foreign Corrupt Practices Act | 2020 | DOJ_CRIMINAL | $233,000,000 |
Teva Pharmaceutical Industries Limited | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | SEC | $236,000,000 |
Gilead Sciences | Gilead Sciences | price-fixing or anti-competitive practices | 2024 | private lawsuit-federal | $246,750,000 |
Abbott Laboratories | AbbVie | price-fixing or anti-competitive practices | 2009 | private lawsuit-federal | $250,000,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
Mallinckrodt ARD LLC | Mallinckrodt | False Claims Act and related | 2022 | DOJ_CIVIL | $260,000,000 |
Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Mylan N.V. | Viatris | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $264,000,000 |
Ranbaxy | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $266,729,715 |
Purdue Pharma | Purdue Pharma | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
Teva Pharmaceuticals Industries Ltd. | Teva Pharmaceutical Industries | product safety violation | 2012 | private lawsuit-federal | $270,000,000 |
Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | price-fixing or anti-competitive practices | 2023 | DOJ_ANTITRUST | $275,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | FL-AG | $278,826,499 |
Dey Inc. | Viatris | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
Roxane Laboratories Inc. | Hikma Pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
Celgene Corp. | Bristol-Myers Squibb | False Claims Act and related | 2017 | USAO | $280,000,000 |
Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | DOJ_CRIMINAL | $283,177,348 |
Pfizer | Pfizer | drug or medical equipment safety violation | 2013 | private lawsuit-federal | $288,000,000 |
Merck | Merck | False Claims Act and related | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $290,000,000 |
Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $292,969,482 |
Bristol-Myers Squibb | Bristol-Myers Squibb | fraud | 2005 | USAO | $300,000,000 |
Indivior plc | Indivior PLC | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Daiichi Sankyo Inc. | Daiichi Sankyo | product safety violation | 2017 | private lawsuit-federal | $300,000,000 |
Bausch Health Companies Inc. | Bausch Health | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $300,000,000 |
Johnson and Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2023 | CA-AG | $302,000,000 |
Teva Pharmaceuticals, Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | NY-AG | $313,343,793 |
Pfizer, Inc. | Pfizer | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
Abbott Laboratories | AbbVie | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $339,148,643 |
Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | DOJ_CIVIL | $345,000,000 |